Search
Midostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potent...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersDalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Synonyms: p-AminopyridineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesVicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was develop...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesOdanacatib
go.drugbank.com/drugs/DB06670InvestigationalOdanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesVilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight ga...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsLaquinimod
go.drugbank.com/drugs/DB06685InvestigationalLaquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries. It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. I...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesArtemether
go.drugbank.com/drugs/DB06697ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersFesoterodine
go.drugbank.com/drugs/DB06702ApprovedFesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesMethyltestosterone
go.drugbank.com/drugs/DB06710ApprovedInvestigationalA synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methylt...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNorelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalNorelgestromin is a progestin used as the progestational component of combined hormonal contraceptives. It is administered transdermally in combination with the estrogen ethinyl estradiol, delivering both hormones systemically over a 7-d...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates